Warfarin vs non‐vitamin K oral anticoagulants for left atrial appendage thrombus: A meta‐analysis

Novel oral anticoagulants (NOACs) are commonly used for thromboembolic risk reduction and treatment of pulmonary embolism and deep venous thrombosis. However, data regarding their efficacy and safety in comparison to warfarin for left atrial appendage thrombus is limited.

[1]  S. Saba,et al.  Non‐vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter , 2019, Pacing and clinical electrophysiology : PACE.

[2]  Yan He,et al.  Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients , 2019, Journal of Thrombosis and Thrombolysis.

[3]  M. Reichman,et al.  Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. , 2019, The American journal of medicine.

[4]  J. Waltenberger,et al.  Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis , 2018, European Journal of Medical Research.

[5]  Anna Plitt,et al.  A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism , 2018, Cardiology and Therapy.

[6]  E. Hylek,et al.  Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants , 2018, Journal of the American Heart Association.

[7]  Paul L. Hess,et al.  Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration , 2017, BMC Cardiovascular Disorders.

[8]  Jiafeng Lin,et al.  Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis , 2016, Medicine.

[9]  Joshua D. Brown,et al.  Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation , 2016, Journal of managed care & specialty pharmacy.

[10]  G. Lip,et al.  Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). , 2016, American heart journal.

[11]  Fei Xie,et al.  Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation. , 2015, International journal of cardiology.

[12]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[13]  Mien-Cheng Chen,et al.  Left Atrial or Left Atrial Appendage Thrombus Resolution After Adjustment of Oral Anticoagulant Treatment. , 2019, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[14]  G. Breithardt,et al.  Rationale and design of the RE-LATED AF—AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus—Effects of Dabigatran in patients with Atrial Fibrillation , 2015, Clinical Research in Cardiology.